ACE and type 2 diabetes mellitus: The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) found that treatment with the angiotensin converting enzyme (ACE) inhibitor trandolapril, either as monotherapy or combined with the calcium channel blocker verapamil, halved the incidence of microalbuminuria over a median observation period of 3.6 years in 1,204 hypertensive patients with type 2 diabetes and normoalbuminuria compared to verapamil alone or placebo [3].